Bristol-Myers Squibb Co. BMY, -5.38% said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main goal. The drug company said the Phase 3 study called CheckMate-331 evaluating its opdivo in patients with the disease who relapsed following platinum-based chemotherapy failed to meet its primary endpoint of overall survival. “Small cell lung cancer is a highly aggressive disease in which significant unmet need remains,” said Sabine Maier, development lead, thoracic cancers, at Bristol-Myers Squibb. “We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer.” Shares were slightly higher premarket, but have fallen 6.1% in 2018, while the S&P 500 SPX, -2.06% has gained 2.1%.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.